West China Lecheng Hospital has initiated outpatient treatment with Vorasidenib, a first-in-class targeted therapy, for Chinese patients with IDH-mutant diffuse glioma. This follows its approval as a clinically urgently needed imported drug in the Boao Lecheng International Medical Tourism Pilot Zone, marking the first use of Vorasidenib in Asia prior to its European availability.
Vorasidenib, a dual inhibitor of IDH1 and IDH2, represents a significant advancement in glioma treatment. Gliomas are the most common primary malignant brain tumors, with over 90% of patients experiencing recurrence and disease progression despite current treatments like surgical resection and chemoradiation.
Significance of IDH Mutation
IDH mutations play a pivotal role in the development of glioma. Vorasidenib offers a targeted approach, providing significant benefits compared to current treatments, especially for those with IDH1 and IDH2 mutations.
Servier's Commitment
Manuel RUIZ, General Manager of Servier China, emphasized the company's commitment to addressing patient needs and improving treatment outcomes. "The success of Voranigo's launch in Bo'ao is rooted in the belief that every patient should have access to the best treatments available, and we are committed to making that a reality here in China."
Real-World Study in Progress
A real-world study is being conducted in Boao Lecheng to evaluate the safety and efficacy of Vorasidenib in Chinese patients. This study aims to expedite the research process, potentially delivering results 1-2 years faster than traditional clinical trials. Vorasidenib has already secured approval for clinical trial III from the National Medical Products Administration and is preparing for official registration in China.
